Overview

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-06-14

Target enrollment:

Participant gender:

Summary

This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).

Phase:

PHASE4

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

mepolizumab